http://www.chevyautoclub.com/remote-start-recommendation
The drug, known now as TTP-515, was developed to treaf obesity. Yet it has also shown significant promise in early clinical trialx in treating a medicap condition that affects as much as 40 percent of the worldwidefemalwe population. Several pharmaceutical companies are racing to producee thefirst so-called “femaled Viagra,” which has a potential market north of $4 billion “Right now, we have nothing, nothing, to offed these women. If this drug succeedss in furtherclinical trials, they are goint to make a fortune,” says Dr.
Jim Pfaus, an expert in the neurobiologuy of sexual behavior at Concordiz Universityin Montreal, who assessed the resultsa of TTP-515 in animal tests he conducted. “The world will know about TransTech Inmany ways, TransTech’s reputation in the biotech worlrd is well established. It has attracted more than $300 million in recenyt years in deals and collaborations with pharma giantsd suchas , Merck and for its potential drugas for Alzheimer’s disease, diabetes and cancer. But a drug that coulsd possibly stimulatea woman’s interest in initiating sex? TransTech’ brand, as Pfaus speculates, woul surely soar.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment